Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers

The receptor for advanced glycation end products (RAGE), a well-known player of diabetes mellitus (DM)-related morbidities, was supposed to be involved in coronavirus disease-19 (COVID-19), but no data exist about COVID-19, DM, and the soluble RAGE (sRAGE) forms. We quantified total sRAGE and its forms, the endogenously secretory esRAGE and the membrane-cleaved cRAGE, in COVID-19 patients with and without DM and in healthy individuals to explore how COVID-19 may affect these molecules and their potential role as biomarkers. Circulating sRAGE and esRAGE were quantified by enzyme-linked-immunosorbent assays. cRAGE was obtained by subtracting esRAGE from total sRAGE. sRAGE, esRAGE, cRAGE, and the cRAGE/esRAGE ratio did not differ between DM and non-DM patients and had the same trend when compared to healthy individuals. Levels of total sRAGE, cRAGE, and cRAGE/esRAGE ratio were upregulated, while esRAGE was downregulated. The lack of difference between DM and non-DM COVID-19 patients in the levels of sRAGE and its forms supports the hypothesis that in COVID-19 the RAGE system is modulated regardless of glycemic control. Identifying how sRAGE and its forms associate to COVID-19 prognosis and the potential of RAGE as a therapeutic target to control inflammatory burden seem of relevance to help treatment of COVID-19.

[1]  Shenmin Zhang,et al.  SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 , 2020, Journal of Hematology & Oncology.

[2]  B. Krishnamachary,et al.  The Potential Role of Extracellular Vesicles in COVID-19 Associated Endothelial injury and Pro-inflammation , 2020, medRxiv.

[3]  Jeremy L. Praissman,et al.  Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor , 2020, Cell Host and Microbe.

[4]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[5]  A. Belfiore,et al.  COVID-19 and Diabetes: The Importance of Controlling RAGE , 2020, Frontiers in Endocrinology.

[6]  R. Ureshino,et al.  SARS‐CoV‐2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Rojas,et al.  SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE? , 2020, Inflammation Research.

[8]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[9]  M. Zuin,et al.  Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome , 2020, Journal of Clinical Virology.

[10]  L. Egaña-Gorroño,et al.  Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models , 2020, Frontiers in Cardiovascular Medicine.

[11]  F. Ambrogi,et al.  Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health , 2020, Journal of clinical medicine.

[12]  Shuzhen Chen,et al.  Exosome-Mediated Transfer of ACE2 (Angiotensin-Converting Enzyme 2) from Endothelial Progenitor Cells Promotes Survival and Function of Endothelial Cell , 2020, Oxidative medicine and cellular longevity.

[13]  Merlin C. Thomas,et al.  Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis , 2018, The Journal of clinical investigation.

[14]  M. Böhm,et al.  Suppressed MMP-9 Activity in Myocardial Infarction-Related Cardiogenic Shock Implies Diminished Rage Degradation , 2017, Shock.

[15]  T. Oury,et al.  All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. , 2017, Paediatric respiratory reviews.

[16]  G. Banfi,et al.  Irisin: A Potential Link between Physical Exercise and Metabolism—An Observational Study in Differently Trained Subjects, from Elite Athletes to Sedentary People , 2017, Journal of diabetes research.

[17]  G. Schmitz,et al.  Expression of the Receptor for Advanced Glycation End Products in Epicardial Fat: Link with Tissue Thickness and Local Insulin Resistance in Coronary Artery Disease , 2015, Journal of diabetes research.

[18]  F. Antohe,et al.  High-mobility group box 1 enhances the inflammatory process in diabetic lung. , 2015, Archives of biochemistry and biophysics.

[19]  D. Betteridge,et al.  Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes , 2015, PloS one.

[20]  A. Schmidt.  Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. , 2015, Vascular pharmacology.

[21]  B. Astor,et al.  sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death , 2013, Diabetes.

[22]  B. Freedman,et al.  Basic Performance of an Enzymatic Method for Glycated Albumin and Reference Range Determination , 2011, Journal of diabetes science and technology.

[23]  C. DeCarli,et al.  Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). , 2011, Atherosclerosis.

[24]  F. Santilli,et al.  Soluble forms of RAGE in internal medicine , 2009, Internal and emergency medicine.

[25]  E. Kojro,et al.  Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases* , 2008, Journal of Biological Chemistry.

[26]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  A. Rossi,et al.  Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[29]  S. Imamura,et al.  Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[30]  P. Rogalla,et al.  Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.

[31]  Mamoru Takahashi,et al.  An enzymatic method for the measurement of glycated albumin in biological samples. , 2002, Clinica chimica acta; international journal of clinical chemistry.